2026 年 03 月 29 日 阿里巴巴（BABA.N）：开源千问 Qwen3.5-Plus 模型，以"效率革命"重塑 AI 竞争格局 —计算机行业点评报告 推荐(维持) 事件 分析师：任春阳 S1050521110006 rency@cfsc.com.cn 分析师：谢孟津 S1050525120001 xiemj@cfsc.com.cn 行业相对表现 | 表现 | 1M | 3M | 12M | | --- | --- | --- | --- | | 计算机(申万) | -13.7 | -5.3 | 2.7 | | 沪深 300 | -4.4 | -2.9 | 15.0 | 市场表现 -20 -10 0 10 20 30 40 (%) 计算机 沪深300 资料来源：Wind，华鑫证券研究 相关研究 2026 年 2 月 16 日，阿里巴巴集团正式发布新一代大模型系 列"Qwen3.5"，并开源其首款模型——Qwen3.5-397B-A17B （亦称 Qwen3.5-Plus）。该模型是一款原生多模态基础模 型，在推理、编程、智能体（Agent）能力及多模态理解方面 表现卓越。其采用创新的混合专家（MoE） ...

Market Sentiment - The current market sentiment score is 63, indicating a "relatively hot" market condition, which suggests strong investor confidence [5][8][19] Hot Themes Tracking - **Banking Sector**: The banking sector is characterized by low valuations and high dividend yields (over 4.5% for half of the stocks), making it a stable investment choice amid economic slowdown and increased market volatility. Key stocks include Agricultural Bank of China (601288) and Ningbo Bank (002142) [5] - **Power Equipment Sector**: The demand for high-power and high-stability transformers is surging due to the significant energy consumption of global AI data centers. The supply-demand imbalance is severe, with delivery times in the US reaching 127 weeks. China's State Grid is set to invest 4 trillion yuan in new power systems during the 14th Five-Year Plan, providing long-term order support for the industry. Relevant stocks include China Western Power (601179) and TBEA Co., Ltd. (600089) [5] - **Yangtze River High-Speed Rail**: The successful completion of a major construction task by the world's largest diameter high-speed rail shield machine is a key milestone for the Yangtze River high-speed rail project, which has a total investment exceeding 500 billion yuan. This project is expected to boost the value added in upstream and downstream industries by nearly 1.5 trillion yuan. Key stocks include China Railway Industry (600528) and Shenzhou High-Speed Railway (000008) [5] Capital Flow Analysis - The top ten stocks with the highest net inflow include Pingtan Development (000592) with 179.72 million yuan and Guangxun Technology (002281) with 64.78 million yuan, indicating strong investor interest in these companies [9] - The top ten stocks with the highest net outflow include Sunshine Power (300274) with -167.58 million yuan and Luxshare Precision (002475) with -132.44 million yuan, reflecting a bearish sentiment towards these stocks [11] Industry Overview - The report highlights significant capital inflows into the agriculture, defense, and construction materials sectors, while the electronics and public utilities sectors are experiencing notable outflows, indicating shifting investor preferences [15][16]

Investment Rating - The report maintains a "Buy" investment rating for the company [10] Core Insights - The company has shown significant improvement in profitability, with strong growth in electrolyte sales [5] - The demand for battery materials remains robust, leading to increased capacity utilization [6] - The daily chemical materials segment has become a new growth point, with ongoing efforts to expand both domestic and international markets [7] Summary by Sections Financial Performance - In 2025, the company achieved revenue of approximately 166.50 billion yuan, a year-on-year increase of 33%, and a net profit attributable to shareholders of about 13.62 billion yuan, up 181.43% [4] - The forecast for 2026-2028 projects revenues of 301.6 billion yuan, 381.5 billion yuan, and 475.7 billion yuan respectively, with corresponding EPS of 2.92 yuan, 3.46 yuan, and 4.01 yuan [10][12] Product Performance - The company's core product, electrolyte, saw sales exceed 720,000 tons in 2025, representing a growth of approximately 44% [5] - The company has reached a near full production capacity of 850,000 tons for electrolytes and is expected to break through several key technologies in 2026 [5] Market Expansion - The daily chemical materials business achieved sales of over 120,000 tons in 2025, with a year-on-year growth of 10.69% [7] - The company is actively investing in the daily chemical sector and expanding its international channels [7]

Investment Rating - The report assigns a "Buy" investment rating for the company, marking its first coverage [8]. Core Insights - The company has significantly expanded its sales scale, achieving a revenue of 8.532 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 58.65%. The net profit attributable to shareholders reached 719 million yuan, up 54.95% year-on-year, driven by sales expansion and profit growth [4]. - The company is actively enhancing its core capabilities, with sales expenses amounting to 198 million yuan, a 45.19% increase year-on-year, and R&D expenses of 672 million yuan, up 31.83% year-on-year, which are expected to support future business growth [4]. - The company showcased its AI full-stack optical interconnection solutions at the OFC Global Optical Communication Conference, including a 3.2T NPO and a 320×320 OCS all-optical switch, addressing key scenarios in cluster interconnection and computing resource scheduling [5]. - The company plans to raise no more than 3.5 billion yuan for projects related to optical connections and high-speed optical transmission, focusing on next-generation pluggable optical modules and advanced optical engine technologies [6]. Financial Projections - Revenue projections for 2025, 2026, and 2027 are 11.757 billion yuan, 15.687 billion yuan, and 19.615 billion yuan, respectively, with corresponding EPS of 1.35 yuan, 1.90 yuan, and 2.48 yuan. The current stock price corresponds to P/E ratios of 63, 44, and 34 times for these years [8][10]. - The company is expected to maintain strong growth rates, with revenue growth rates of 42.1% in 2025, 33.4% in 2026, and 25.0% in 2027 [10]. - The net profit attributable to shareholders is projected to grow to 1.086 billion yuan in 2025, 1.536 billion yuan in 2026, and 1.999 billion yuan in 2027, with growth rates of 64.2%, 41.5%, and 30.1%, respectively [10]. Market Position - The company is positioned to benefit from the rapid development of the optical communication industry, driven by data center upgrades, the explosion of AI technology, and deep coverage of telecom networks [6]. - The company is focusing on high-end products with significant demand and high technical barriers, aiming to enhance its core competitiveness through product structure optimization [6].

Core Insights - The report indicates a neutral market sentiment with a score of 59, suggesting moderate volatility and investor stability [2][9] - Key investment themes identified include banking, power grid equipment, and brokerage firms, each presenting unique opportunities based on current market conditions [6] Banking Sector - The banking sector is characterized by low valuations and high dividend yields, with half of the stocks offering yields exceeding 4.5%. This makes banks a stable investment choice amid economic slowdown and increased market volatility [6] - Notable stocks in this sector include Agricultural Bank of China (601288) and Ningbo Bank (002142) [6] Power Grid Equipment Sector - The demand for high-power and stable transformers is driven by the significant energy consumption of global AI data centers, leading to a supply-demand imbalance. The delivery cycle in the U.S. market has reached 127 weeks [6] - China's State Grid is set to invest 4 trillion yuan during the 14th Five-Year Plan, focusing on ultra-high voltage and smart distribution networks, providing long-term order support for the industry [6] - Relevant stocks include China Xidian (601179) and TBEA Co., Ltd. (600089) [6] Brokerage Firms - Among the listed brokerage firms that have disclosed earnings forecasts, over half reported a year-on-year increase in net profit exceeding 50%, indicating a comprehensive recovery in profitability [6] - The current price-to-book ratio for the sector is 1.37, which is historically low and contrasts sharply with the high growth fundamentals [6] - The draft of the Financial Law is expected to accelerate industry differentiation, benefiting leading brokerage firms. Key stocks include CITIC Securities (600030) and Guotai Junan Securities (601211) [6]

Investment Rating - The report maintains a "Buy" investment rating for Bilibili-W (9626.HK) [2] Core Insights - Bilibili's commercial value is expected to enhance in the AI era, with a focus on improving its monetization capabilities [5][6] - The company is projected to achieve a revenue of 30.348 billion yuan in 2025, with a year-on-year growth of 13.1%, and a net profit of 1.194 billion yuan, marking a return to profitability [5] - The user base is growing, with daily active users reaching 113 million and monthly active users at 366 million by Q4 2025, indicating strong user engagement [5] - Bilibili's advertising business is anticipated to benefit from the attention economy driven by AI, with significant growth potential in brand, performance, and native advertising [6] - The company plans to increase its investment in AI to enhance content understanding and promote AI-assisted creation tools for content creators [7] Financial Projections - Revenue forecasts for 2026-2028 are 32.243 billion yuan, 35.319 billion yuan, and 38.248 billion yuan respectively, with corresponding net profits of 1.802 billion yuan, 2.708 billion yuan, and 3.503 billion yuan [8] - The earnings per share (EPS) are projected to be 4.28 yuan, 6.43 yuan, and 8.32 yuan for 2026, 2027, and 2028 respectively, with price-to-earnings (P/E) ratios of 45, 30, and 23 [8]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 30, 2026 [3]. Core Insights - The innovative drug sector is experiencing a significant configuration opportunity, with major domestic pharmaceutical companies reporting rapid growth in innovative drugs. The development model has shifted from solely relying on financing to a comprehensive approach that includes product commercialization, overseas R&D licensing, and financing [4]. - The Chinese innovative drug market has seen a surge in business development (BD) events, with 49 BD events recorded in 2026, totaling over $33 billion in upfront payments and nearly $570 billion in total deal value. The first quarter of 2026 alone surpassed the total transaction volume of 2024 [4]. - The innovative drug index outperformed the CSI 300 index by 4.44 percentage points during the week of March 21-27, 2026, with a growth rate of 3.03% [4]. Summary by Sections 1. Innovative Drug Highlights - Major domestic pharmaceutical companies like Heng Rui Medicine and China Biopharmaceuticals have reported rapid growth in innovative drugs, with biotech firms like BeiGene and Innovent Biologics turning significant losses into profits [4]. - The trend of Chinese innovative drugs going global is strong, with a notable increase in BD events and a focus on clinical data quality and long-term market value [4]. 2. Tumor Immunotherapy 2.0 Era - China continues to lead in the development of PD-1/VEGF bispecific antibodies, with significant partnerships and clinical advancements. The market potential for PD-1 bispecifics is expected to surpass that of PD-1 monotherapy [5]. - The collaboration between domestic companies and multinational corporations (MNCs) is intensifying, with a focus on clinical data and market rights sharing [5]. 3. New Technologies and Molecules - The ADC (Antibody-Drug Conjugate) sector is witnessing innovation, with new technologies being integrated to overcome limitations of existing ADCs. The introduction of various therapeutic modalities is expected to expand the applicability of ADCs [6]. 4. Small RNA Collaborations - The small RNA sector is seeing increased mergers and collaborations, with significant deals being made to develop innovative therapies for metabolic disorders. The market for small RNA drugs is rapidly industrializing, with notable sales growth for products like Leqvio [7]. 5. Price Control and Raw Materials - The report highlights the price elasticity of certain raw materials, particularly vitamins, which have seen significant price increases due to geopolitical factors and supply chain dynamics. Vitamin E and A prices have risen by 81.98% and 76% respectively since the beginning of the year [9]. 6. CDMO and CXO Trends - The report emphasizes the importance of CDMO (Contract Development and Manufacturing Organization) in driving orders for large products, with recommendations for companies like Yino Science and Pruis [12]. 7. Recommended Companies and Stock Picks - The report suggests focusing on companies leading in innovative drugs, ADC technology, small RNA therapies, and those with pricing power in raw materials. Specific recommendations include Rongchang Biopharmaceuticals, Sunway Biopharma, and others [12][13].

Investment Rating - The report maintains a "Recommended" rating for the automotive industry, particularly focusing on the humanoid robot sector and its potential growth opportunities [2][8]. Core Insights - The Optimus team at Tesla is accelerating towards mass production of humanoid robots, with a factory capable of producing 10 million units under construction. The team is currently hiring extensively, with 147 positions available, and aims to start large-scale production by the end of this year [4]. - The report highlights the overall low positioning of the robotics sector, with a positive outlook for the T-chain as the Optimus Gen3 is expected to be released in April. It suggests prioritizing investments in T-chain companies before the release [5]. - Several automotive companies, including BYD and Great Wall, are expanding their overseas operations, with BYD's international revenue reaching 310.74 billion yuan, accounting for 38.7% of total revenue, a significant increase from the previous year [6][7]. Summary by Sections Humanoid Robot Sector - The humanoid robot index increased by 0.23% this week, with a cumulative return of 81.1% since 2025. The trading volume of the humanoid robot sector accounted for 13.2% of the CSI 2000 index [16]. - Among the sub-sectors, the reducer segment performed relatively well, increasing by 0.8%, while other components like the total assembly and dexterous hands saw slight declines [19]. - Key companies in the robotics sector include Fulin Precision, Slin Intelligent Drive, and Zhenyu Technology, which have shown significant gains [23]. Automotive Sector - The CITIC automotive index fell by 0.2%, outperforming the broader market by 1.2 percentage points. The new energy vehicle index rose by 4.5%, indicating strong performance in that segment [33][36]. - Among tracked companies, Hunan Tianyan and Xiyi Co. saw significant gains, while Huada Technology and Xuelong Group faced substantial declines [41]. - The automotive industry's PE ratio is at 33.3, positioned at the 50.7% percentile over the past four years, indicating a relatively stable valuation environment [50]. Recommended Stocks - The report recommends several stocks, including Mould Technology, Shuanglin Co., and KaiDi Co., all rated as "Buy" based on their growth potential in the humanoid robot and automotive sectors [10][11].

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 30, 2026 [3]. Core Insights - The innovative drug sector is experiencing a significant configuration moment, with major domestic pharmaceutical companies reporting rapid growth in innovative drugs. The development model has shifted from solely relying on financing to a comprehensive approach that includes product commercialization, overseas R&D licensing, and financing [4]. - The Chinese innovative drug market is witnessing a surge in outbound business development (BD) events, with 49 BD events recorded by March 25, 2026, totaling over $33 billion in upfront payments and nearly $57 billion in total deal value [4]. - The innovative drug index outperformed the CSI 300 index by 4.44 percentage points during the week of March 21-27, 2026, with a growth rate of 3.03% [4]. Summary by Sections 1. Innovative Drug Highlights - Major companies like Heng Rui Medicine and China Biopharmaceutical have reported rapid growth in innovative drugs, with biotech firms like BeiGene and Innovent Biologics turning significant losses into profits [4]. - The trend of Chinese innovative drugs going global is strong, with a notable increase in BD events and deal values compared to previous years [4]. 2. Tumor Immunotherapy 2.0 Era - China continues to lead in the development of PD-1/VEGF bispecific antibodies, with significant partnerships and clinical advancements [5]. - The market potential for PD-1 bispecific antibodies is expected to surpass that of single-agent PD-1 therapies, with ongoing collaborations and clinical trials [5]. 3. New Technologies and Molecules - The ADC (Antibody-Drug Conjugate) sector is seeing innovations with new payloads and combinations, with Chinese companies making significant strides in this area [6]. - The introduction of new technologies, such as tumor microenvironment-activated drugs, is expected to expand the applicability of ADCs [6]. 4. Small RNA Collaborations - The small RNA sector is experiencing accelerated collaboration and acquisitions, with significant deals and partnerships being established in 2026 [7]. - The market for small RNA drugs is rapidly industrializing, with notable sales growth for products like Leqvio, which achieved $1.2 billion in sales in the 2025 fiscal year [7]. 5. Price Leadership in Raw Materials - The report highlights the price increases in vitamins and raw materials due to geopolitical tensions and supply chain dynamics, with specific products like Vitamin E and A seeing significant price hikes [9]. - The report notes that certain raw materials have maintained price leadership, allowing for rapid price increases in specific categories [9]. 6. Cost Pass-Through in Gloves - The report discusses the cost increases in nitrile and PVC gloves due to rising raw material prices, with significant price elasticity observed in these products [10]. - The report indicates that the supply chain dynamics are shifting, providing competitive advantages for Chinese manufacturers in the global market [10]. 7. Two-Way Item Management - The management of dual-use items is expected to create pricing advantages for domestic medical products, leveraging China's unique resource endowments [11]. - The report suggests that stricter controls on key materials could enhance the competitive position of Chinese medical products in international markets [11]. 8. Stock Recommendations - The report recommends several companies based on their positioning in innovative drugs, ADCs, small RNA, and raw materials, including Rongchang Biopharmaceutical, Sunway Biopharma, and others [12][13].

1. Report Industry Investment Rating No relevant content provided in the report. 2. Core Viewpoints - The report expects the liability growth rate of the real - sector to decline to around 8.3% in March 2026, and to around 8.0% by the end of 2026. The liability growth rate of the government sector is expected to drop to around 11.5% in March and around 11.6% by the end of 2026. It is recommended that investors control stock and bond positions, focus on short - term and money - market assets, and the equity style is expected to shift towards value - dominance [2][17][18]. - Amid the China - US competition and potential re - valuation of the US technology sector, global funds may flow to China. Attention should be paid to whether the RMB exchange rate enters an appreciation channel. The risk preference may enter a range - bound state, and new funds in the financial market may be limited [6][20]. - In the short term, due to the Iran - US conflict, the A - share market is negatively correlated with international oil prices. Long - term bond prices have stabilized, and ultra - long - term bond prices have risen. The report continues to recommend the Shanghai Composite 50 Index (80% position) and the CSI 1000 Index (20% position) [7][21][22]. - In the de - leveraging cycle, the cost - performance ratio between stocks and bonds favors equities to a limited extent, and the value style is more likely to be dominant. The report recommends an A + H dividend portfolio and an A - share portfolio, mainly concentrated in industries such as banking, telecommunications, petroleum and petrochemicals, and transportation [9][58]. 3. Summary of Each Section 3.1 National Asset - Liability Sheet Analysis Liability Side - In February 2026, the real - sector liability growth rate was 8.4%, up from 8.3% previously. It is expected to decline to around 8.3% in March and remain stable in April. The government debt increased by 223.6 billion yuan last week, higher than the planned 185.4 billion yuan. The government liability growth rate at the end of February was 12.1%, down from 12.6% previously, and is expected to further decline to around 11.5% in March [2][17][18]. - The money market tightened last week. It is still expected that the peak of the money market in March will occur on the 5th. It is estimated that the one - year Treasury bond yield will have a lower limit of about 1.3% and a central value of around 1.4%, with a 10 - basis - point interest rate cut expected in 2026 [3][18]. Asset Side - The physical data from January to February showed a significant improvement compared to December. The two sessions set the annual real economic growth target for 2026 at 4.5 - 5%, and the nominal economic growth target is around 5.0% [19]. 3.2 Stock - Bond Cost - Performance and Stock - Bond Style - Since 2011, China has entered a period of declining potential economic growth, which may have ended in Q4 2024. The government put forward three major policy goals in 2016. Currently, the de - leveraging on the liability side has not ended, but the room for further de - leveraging is limited [6][20]. - Last week, the money market tightened, and the Iran - US conflict dominated the market. The A - share market was bearish, and the bond market was bullish, with the growth style prevailing. The ten - year Treasury bond yield dropped by 1 basis point to 1.82%, and the 30 - year Treasury bond yield dropped by 4 basis points to 2.35%. The stock - bond cost - performance ratio favored bonds [7][21]. 3.3 Industry Recommendation Industry Performance Review - This week, the A - share market declined with shrinking volume. The Shanghai Composite Index fell 1.1%, the Shenzhen Component Index fell 0.8%, and the ChiNext Index fell 1.7%. Among the Shenwan primary industries, non - ferrous metals, public utilities, basic chemicals, pharmaceutical biology, and textile and apparel had the highest gains, while non - bank finance, computer, agriculture, forestry, animal husbandry and fishery, beauty care, and national defense and military industry had the largest declines [29]. Industry Crowding and Trading Volume - As of March 29, the top five crowded industries were electronics, power equipment, non - ferrous metals, communications, and basic chemicals, while the bottom five were beauty care, comprehensive, social services, textile and apparel, and steel. The industries with the largest increase in crowding this week were pharmaceutical biology, non - ferrous metals, public utilities, basic chemicals, and automobiles, while those with the largest decline were computer, communications, power equipment, electronics, and building decoration [30]. - The average daily trading volume of the entire A - share market this week was 2.11 trillion yuan, down from 2.21 trillion yuan last week. Public utilities, coal, social services, pharmaceutical biology, and textile and apparel had the highest year - on - year growth rates in trading volume, while steel, basic chemicals, agriculture, forestry, animal husbandry and fishery, building decoration, and petroleum and petrochemicals had the largest declines [33]. Industry Valuation and Earnings - This week, among the Shenwan primary industries, building materials, basic chemicals, public utilities, petroleum and petrochemicals, and textile and apparel had the largest increases in PE(TTM), while beauty care, computer, agriculture, forestry, animal husbandry and fishery, non - bank finance, and electronics had the largest declines. Industries with high 2024 full - year earnings forecasts and relatively low current valuations compared to history include banking, securities, insurance, pharmaceutical biology, beauty care, new energy, gaming, and consumer electronics [35][36]. Industry Prosperity - In terms of external demand, there were both increases and decreases. The global manufacturing PMI rose from 50.9 in February to 51.9, and most major economies' PMIs increased. The CCFI index rose 1.6% week - on - week, and port cargo throughput rebounded. South Korea's export growth rate decreased slightly in February and increased to 50.4% in the first 20 days of March. Vietnam's export growth rate decreased from 34.3% in January to 6.3% in February [40]. - In terms of domestic demand, second - hand housing prices declined last week, and quantity indicators showed mixed trends. Highway truck traffic volume rebounded, and the capacity utilization rate of ten industries rebounded to around the historical median level in March. Automobile trading volume was relatively weak seasonally, new - home sales were at a historical low, and second - hand home sales were at a historical high [40]. Public Fund Market Review - In the fourth week of March (March 23 - 27), most active public equity funds outperformed the CSI 300. As of March 27, the net asset value of active public equity funds was 3.81 trillion yuan, up from 3.66 trillion yuan in Q4 2024 [55]. Industry Recommendation - In the de - leveraging cycle, the cost - performance ratio between stocks and bonds favors equities to a limited extent, and the value style is more likely to be dominant. The recommended A + H dividend portfolio includes 13 A + H stocks, and the A - share portfolio includes 20 A - share stocks, mainly concentrated in industries such as banking, telecommunications, petroleum and petrochemicals, and transportation [9][58].